Clearside Biomedical, Inc. (CLSD): Price and Financial Metrics

Clearside Biomedical, Inc. (CLSD): $1.20

0.02 (+1.69%)

POWR Rating

Component Grades














  • CLSD scores best on the Value dimension, with a Value rank ahead of 82.18% of US stocks.
  • The strongest trend for CLSD is in Momentum, which has been heading up over the past 179 days.
  • CLSD ranks lowest in Growth; there it ranks in the 7th percentile.

CLSD Stock Summary

  • With a year-over-year growth in debt of 4,166.76%, CLEARSIDE BIOMEDICAL INC's debt growth rate surpasses 99.31% of about US stocks.
  • Revenue growth over the past 12 months for CLEARSIDE BIOMEDICAL INC comes in at 584.38%, a number that bests 98.21% of the US stocks we're tracking.
  • CLEARSIDE BIOMEDICAL INC's shareholder yield -- a measure of how much capital is returned to stockholders via dividends and buybacks -- is -46.28%, greater than the shareholder yield of only 11.58% of stocks in our set.
  • If you're looking for stocks that are quantitatively similar to CLEARSIDE BIOMEDICAL INC, a group of peers worth examining would be SLDP, AKTS, MRKR, ADCT, and YMAB.
  • Visit CLSD's SEC page to see the company's official filings. To visit the company's web site, go to

CLSD Valuation Summary

  • In comparison to the median Healthcare stock, CLSD's price/earnings ratio is 166.81% lower, now standing at -15.5.
  • Over the past 79 months, CLSD's price/earnings ratio has gone down 8.2.

Below are key valuation metrics over time for CLSD.

Stock Date P/S P/B P/E EV/EBIT
CLSD 2022-11-25 2.7 3.8 -15.5 -10.9
CLSD 2022-11-23 2.7 3.8 -15.5 -10.9
CLSD 2022-11-22 2.6 3.7 -15.0 -10.4
CLSD 2022-11-21 2.6 3.7 -15.0 -10.4
CLSD 2022-11-18 2.7 3.9 -15.9 -11.3
CLSD 2022-11-17 3.0 4.4 -17.8 -13.1

CLSD Growth Metrics

    The 5 year price growth rate now stands at -74.93%.
  • The 3 year net cashflow from operations growth rate now stands at 98.29%.
  • Its 4 year net cashflow from operations growth rate is now at 24.18%.
CLSD's revenue has moved up $24,511,000 over the prior 33 months.

The table below shows CLSD's growth in key financial areas (numbers in millions of US dollars).

Date Revenue Operating Cash Flow Net Income to Common Stock
2022-09-30 26.684 -2.704 -4.575
2022-06-30 29.492 0.204 -1.635
2022-03-31 29.888 -1.303 0.083
2021-12-31 29.575 -10.733 0.376
2021-09-30 3.899 -20.223 -25.445
2021-06-30 4.257 -19.606 -22.991

CLSD's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
  • CLSD has a Quality Grade of C, ranking ahead of 52.15% of graded US stocks.
  • CLSD's asset turnover comes in at 0.183 -- ranking 206th of 681 Pharmaceutical Products stocks.
  • GLYC, MDVL, and XENE are the stocks whose asset turnover ratios are most correlated with CLSD.

The table below shows CLSD's key quality metrics over time.

Period Asset Turnover Gross Margin ROIC
2021-06-30 0.183 1 3.825
2021-03-31 0.186 1 3.961
2020-12-31 0.397 1 3.928
2020-09-30 0.452 1 4.357
2020-06-30 0.274 1 13.716
2020-03-31 0.232 1 -11.517

CLSD Price Target

For more insight on analysts targets of CLSD, see our CLSD price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $11.60 Average Broker Recommendation 1.58 (Moderate Buy)

CLSD Stock Price Chart Interactive Chart >

Price chart for CLSD

CLSD Price/Volume Stats

Current price $1.20 52-week high $3.38
Prev. close $1.18 52-week low $1.00
Day low $1.16 Volume 63,460
Day high $1.20 Avg. volume 424,686
50-day MA $1.22 Dividend yield N/A
200-day MA $1.53 Market Cap 72.23M

Clearside Biomedical, Inc. (CLSD) Company Bio

Clearside Biomedical, a biopharmaceutical company, develops drug therapies to treat chronic blinding diseases of the eye. The company was founded in 2011 and is based in Alpharetta, Georgia

CLSD Latest News Stream

Event/Time News Detail
Loading, please wait...

CLSD Latest Social Stream

Loading social stream, please wait...

View Full CLSD Social Stream

Latest CLSD News From Around the Web

Below are the latest news stories about CLEARSIDE BIOMEDICAL INC that investors may wish to consider to help them evaluate CLSD as an investment opportunity.

Clearside Biomedical to Participate in Multiple Upcoming Investor and Ophthalmology Conferences in November and December 2022

ALPHARETTA, Ga., Nov. 22, 2022 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (NASDAQ:CLSD), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space (SCS®), announced today that management will participate in the following conferences in November and December 2022: BTIG Ophthalmology DayFireside ChatTuesday, November 29, 2022 at 10:30 a.m. ET Piper Sandler 34th Annual Healthcare ConferenceCorporate PresentationThursday, Decemb

Yahoo | November 22, 2022

Clearside Biomedical Third Quarter 2022 Earnings: Beats Expectations

Clearside Biomedical ( NASDAQ:CLSD ) Third Quarter 2022 Results Key Financial Results Revenue: US$266.0k (down 91% from...

Yahoo | November 11, 2022

Clearside Biomedical (CLSD) Gets a Buy from H.C. Wainwright

H.C. Wainwright analyst Yi Chen reiterated a Buy rating on Clearside Biomedical (CLSD - Research Report) today and set a price target of $6.00. The company's shares closed yesterday at $1.28.According to TipRanks, Chen is an analyst with an average return of -26.0% and a 25.82% success rate. Chen covers the Healthcare sector, focusing on stocks such as Veru, Applied DNA Sciences, and Aslan Pharmaceuticals.Currently, the analyst consensus on Clearside Biomedical is a Moderate Buy with an average price target of $6.50, which is a 407.81% upside from current levels. In a report released yesterday, JMP Securities also reiterated a Buy rating on the stock with a $7.00 price target.

Catie Powers on TipRanks | November 10, 2022

Analysts Offer Insights on Healthcare Companies: Armata Pharmaceuticals (ARMP) and Clearside Biomedical (CLSD)

There's a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Armata Pharmaceuticals (ARMP – Research Report) and Clearside Biomedical (CLSD – Research Report) with bullish sentiments. Armata Pharmaceuticals (ARMP) Ladenburg Thalmann & Co. analyst Michael Higgins maintained a Buy rating on Armata Pharmaceuticals today and set a price target of $9.00. The company's shares closed last Wednesday at $3.28, close to its 52-week low of $2.82. According to, Higgins is a 3-star analyst with an average return of -11.4% and a 43.8% success rate.

Brian Anderson on TipRanks | November 10, 2022

Analyst Bumps Up Clearside Biomedical Target Price After Encouraging Trial Data

Wednesday, Clearside Biomedical Inc (NASDAQ: CLSD) announced positive results from its OASIS Phase 1/2a trial of CLS-AX (axitinib injectable suspension) in neovascular age-related macular degeneration (wet AMD) patients. HC Wainwright views the 6-month results as very encouraging, considering that the enrolled patients have active subfoveal choroidal neovascularization (CNV) secondary to AMD with fluid. Hence the analyst has increased the probability of approval for CLS-AX to 25% from 20%, with

Yahoo | November 10, 2022

Read More 'CLSD' Stories Here

CLSD Price Returns

1-mo -11.11%
3-mo -11.76%
6-mo -7.69%
1-year -63.41%
3-year -30.23%
5-year -82.86%
YTD -56.36%
2021 0.36%
2020 -5.52%
2019 171.03%
2018 -84.71%
2017 -21.70%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from!

Page generated in 0.8749 seconds.